Overall. The University of Iowa/Mayo Clinic Lymphoma SPORE (SPORE) is a dynamic, productive, translational cancer research program based at two comprehensive cancer centers that was first funded in 2002 and competitively renewed in 2007 and 2012. At the center of the ongoing success of the SPORE is the collaborative interaction between investigators at Iowa and Mayo, as well as SPORE basic laboratory, clinical and population science investigators focused on lymphoma. The overall goal of the SPORE is to support innovative, interactive, rigorous translational lymphoma research that leverages the expertise of laboratory, clinical and population science expertise at both institutions. Over the last funding period, the SPORE has been highly productive as demonstrated by identification of new tumor markers and prognostic indices that are being used clinically; scientific findings that led to innovative clinical trials both within and outside the SPORE; multiple publications with many authored by investigators from both institutions; and brisk accrual to translational clinical trials. The SPORE was involved in multiple productive vertical and horizontal collaborations with other national and international academic institutions and organizations. For example, the UI/MC Molecular Epidemiology Resource based in the SPORE is a vital resource for both SPORE research and research projects supported by other grants. It served as the foundation for the funding of the Lymphoma Epidemiology of Outcomes (LEO) Cohort (U01 CA195568) that includes 6 additional institutions, thereby enhancing the scope and diversity of research facilitated by the SPORE. The current proposal includes 4 major research projects. While all of the projects are new, they are based on research results obtained over the past funding period. Project 1 will investigate why the innate immune system (monocyte/macrophage) is suppressed in lymphoma and aims to overcome that suppression with a novel SIRP?-Fc in a phase I trial. Project 2 focuses on enhancing the clinical T-cell response by modifying the lymphoma microenvironment to augment antigen release, presentation of antigen, and T cell activation and combining it with anti-PD1 therapy of NHL. Project 3 is investigating the dysregulated signaling pathways (TRAF3 and GSK3) that regulate glucose hypermetabolism in aggressive lymphoma. They will test a novel GSK3 inhibitor in a phase I trial. Project 4 is a Population Science project will test a combination of germline (host) and somatic (tumor) genomic biomarkers, tumor gene expression, and clinical factors to predict at diagnosis which immunochemotherapy-treated FL patients will have an early clinical failure. The SPORE also includes Developmental Research and Career Enhancement Programs to pursue novel translational concepts in lymphoma research and new investigators through the programs respectively. Finally, the SPORE will enhance the infrastructure that supports translational lymphoma research at both institutions through shared core resources in Administration, Biostatistics and Bioinformatics, Biospecimens, and Clinical Research.
Overall The University of Iowa / Mayo Clinic Lymphoma SPORE is a highly productive research program based at two NCI designated comprehensive cancer centers. The goal of the SPORE is to support investigators at both institutions with expertise in basic lymphoma biology, genetics, clinical research and epidemiology as they work together to translate basic science advances into improved care for lymphoma patients. SPORE research projects focus on the lymphoma tumor microenvironment, lymphoma immunotherapy, understanding and leveraging the relationship between targeted lymphoma therapy and metabolism, and using genetics to predict outcome in a common form of lymphoma.
|Ravi, Praful; Kumar, Shaji K; Cerhan, James R et al. (2018) Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J 8:26|
|Thanarajasingam, Gita; Minasian, Lori M; Baron, Frederic et al. (2018) Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 5:e563-e598|
|Pophali, Priyanka A; Ip, Andrew; Larson, Melissa C et al. (2018) The association of physical activity before and after lymphoma diagnosis with survival outcomes. Am J Hematol 93:1543-1550|
|McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182|
|Shenoy, Niraj; Creagan, Edward; Witzig, Thomas et al. (2018) Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. Cancer Cell 34:700-706|
|Maurer, M J; Habermann, T M; Shi, Q et al. (2018) Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials. Ann Oncol 29:1822-1827|
|Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096|
|Ammann, Eric M; Shanafelt, Tait D; Wright, Kara B et al. (2018) Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. Leuk Lymphoma 59:643-649|
|Chapuy, Bjoern; Stewart, Chip; Dunford, Andrew J et al. (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690|
|Leal, Alexis D; Allmer, Cristine; Maurer, Matthew J et al. (2018) Variability of performance status assessment between patients with hematologic malignancies and their physicians. Leuk Lymphoma 59:695-701|
Showing the most recent 10 out of 387 publications